AR and Familial prostate cancer: Specifically, the implementation of siltuximab, an anti-IL-6 monoclonal antibody, and ruxolitinib, a JAK kinase inhibitor operating upstream of STAT, has been shown to hinder the development of an androgen receptor (AR)-independent, neuroendocrine-like phenotype in both human prostate cancer cell lines and murine models [215].